rinucumab/aflibercept intravitreal (REGN2176-3)
/ Regeneron, Bayer
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 20, 2017
CAPELLA: Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
(clinicaltrials.gov)
- P2; N=505; Terminated; Sponsor: Regeneron Pharmaceuticals; Active, not recruiting ➔ Terminated
Trial termination • Age-related Macular Degeneration • Biosimilar • Complement-mediated Rare Disorders • Gene Therapies • Ophthalmology
1 to 1
Of
1
Go to page
1